Introduction: Dentitric cell-cytokine induced killer cell infusion is a beneficial immunotherapy for breast cancer among Chinese women. This study aimed to verify the prognostic value of cellular immunity among patients receiving infusions.
Methods: 251 female breast cancer patients participated in the study. Mononuclear cells were harvested from peripheral blood and expanded in vitro. With adequate cell counts, the cultured cells were infused into body. After cell infusion, the cellular immunity was measured by flow cytometry. Progression-free and overall survival were estimated by Kaplan-Meier method with Log-rank test. Cox hazard proportion regression model was used to estimate the hazard ratio and 95% confidence interval.
Results: Proportion of CD4+CD25+ T lymphocyte had a dose-relationship with overall survival (p<0.05), but not progression-free survival. The overall survival was 156 months among patients with lower proportion of CD4+CD25+ T cells compared with 76 months among patients with higher proportion (p<0.05). Higher proportion was associated with a death risk increased by 69% (HR=1.69, 95%CI 1.07, 2.68). Among advanced patients (≥stage III), higher proportion of regulatory T cells were related with hazard ratio of 1.78 (95%CI 1.10, 2.91).
Conclusion: CD4+CD25+ regulatory T lymphocytes were a potential indicator for prognosis of breast cancer patients with the immunotherapy of dentitric cell-cytokine induced killer cells, especially among advanced stage. It might integrated with treatment for further management.
Citation Format: Qing-Kun Song, Jun Ren, Xiao-Li Wang, Xin-Na Zhou, Hua-Bing Yang, Yu-Chen Li, Jiang-Ping Wu. CD4+CD25+ regulatory T lymphocytes: Prognostic indicator of Chinese breast cancer patients receiving dentitric cells-cytokine induced killer cells infusion. [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy: A New Chapter; December 1-4, 2014; Orlando, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2015;3(10 Suppl):Abstract nr B14.
- ©2015 American Association for Cancer Research.